Products Approved for Other Bioterrorism Emergencies

Botulism due to Clostridium botulinum toxin

• BabyBIG [Botulism Immune Globulin Intravenous (Human) (BIG-IV)] (CBER)
• BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] (CBER)

Ebola Virus Disease (EVD)

• Ervebo (Ebola Zaire Vaccine, Live) (CBER)
• First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response
• Ebola Preparedness and Response Updates from FDA

Glanders and Melioidosis due to Burkholderia mallei and B. pseudomallei, respectively

• No approved therapeutics

Plague due to Yersinia pestis

• Ciprofloxacin
• Doxycycline and Other Tetracyclines
• Levofloxacin
  • FDA approves new antibacterial treatment for plague
• Moxifloxacin
  • FDA approves additional antibacterial treatment for plague
• Streptomycin (not readily available in the U.S.)

Smallpox due to Variola major and Variola minor

• TPOXX (tecovirimat)
  • FDA approves the first drug with an indication for treatment of smallpox
• Jynneos Smallpox and Monkeypox Vaccine, Live, Non-Replicating (CBER)
  • FDA approves first live, non-replicating vaccine to prevent smallpox and monkeypox
• Vaccina Immune Globulin Intravenous (Human) (VIGIV) (CBER)
• Smallpox (CBER)
• Smallpox Preparedness and Response Updates from FDA
• Smallpox (Variola) Infection:  Developing Drugs for Treatment or Prevention Guidance for Industry (2019)

Tularemia due to Francisella tularensis

• Doxycycline and Other Tetracyclines
• Streptomycin (not readily available in the U.S.)

Zika Virus Disease

• No approved therapeutics
• Zika Virus Response Updates from FDA